Despite remarkable advances in histology pattern recognition recently, automated image analysis is still out of reach for many common pathology applications in the pharmaceutical industry. Frequently there simply is not enough information in the stains utilized in most IHC and H&E studies to provide reliable pattern recognition results without substantial manual curation after analysis. In addition, there remains an unmet need for multiplexing in IHC in brightfield applications beyond one or two proteins.
We have developed a patent pending approach to both feature recognition and multiplexing called Feature Analysis on Consecutive Tissue Sections (FACTS).
The FACTS process requires only minimal changes to current histology practice, and the labor costs are less than what is required for running multiple IHC markers in clinical or preclinical laboratories. Validation for both GLP or CLIA can be done without substantial modifications to common histopathology laboratory practices.
The complete FACTS process was presented at Pathology Visions 2010 in San Diego.
Poster 1: Development and Validation of FACTS
Poster 2: Applications of FACTS in NSCLC and Kidney Glomeruli
Platform Presentation 1: Multiplexing IHC in Regulated Environments
Platform Presentation 2: Practical approaches to xenograft analysis
It was also presented at the 2010 Biosurfaces Conference:Digital Histopathology and Feature Analysis on Consecutive Tissue Sections (FACTS) to Determine Biocompatibility of Biomedical Implants
FACTS compared with other multiplexing techniques in tissues
